Cogent Biosciences Inc. (NASDAQ:COGT) is a top emerging technology stock to invest in, with JPMorgan raising its price target to $67. The company announced positive results from the APEX Part 2 trial for bezuclastinib, showing an ORR of 57% based on modified criteria and well-tolerated side effects.

Bezuclastinib, a KIT D816V inhibitor, demonstrated a 57% ORR in the APEX trial, with minimal side effects and infrequent dose reductions. This marks the third successful pivotal trial for the drug, leading to plans for an NDA submission in H1 2026 and commercial launches in H2 of that year.

Cogent Biosciences Inc. (NASDAQ:COGT) develops precision therapies for genetically defined diseases. While COGT shows promise as an investment, other AI stocks may offer greater upside potential. For insights on undervalued AI stocks with significant growth potential, check out our free report on the best short-term AI stock.

Read more at Yahoo Finance: JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update